Ashton Thomas Private Wealth LLC boosted its stake in Abbott Laboratories by 10.4% in the fourth quarter, owning 45,803 shares worth $5,181,000. Other institutions like Welch Group LLC, Bath Savings Trust Co, Bank Pictet & Cie Europe AG, Simplify Asset Management Inc., and Pensionfund Sabic have also added to their positions in ABT.
Analysts have been optimistic about Abbott Laboratories, with Citigroup, Wells Fargo & Company, Evercore ISI, and Royal Bank of Canada all providing 'buy' or 'outperform' ratings. The stock currently has a consensus rating of 'Moderate Buy' with a target price of $137.19.
Abbott Laboratories' stock opened at $134.90, with a 12-month range of $99.71 to $141.23. The company reported solid quarterly earnings, meeting EPS estimates and posting revenue of $10.97 billion. The firm also declared a quarterly dividend of $0.59 per share.
In insider trading news, EVP Daniel Gesua Sive Salvadori and SVP Eric Shroff recently sold shares of Abbott Laboratories. The company remains focused on its four key segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
Reference from News: Ashton Thomas Private Wealth LLC Has $5.18 Million Holdings in Abbott Laboratories (NYSE:ABT)